
OB/GYN patient complaints up 29% over previous year: Ontario's patient ombudsman
A pregnant woman is examined as she waits to give birth at a public hospital in Rio de Janeiro on Wednesday, July 25, 2012. THE CANADIAN PRESS/AP, Felipe Dana
TORONTO — New data shows more people are filing complaints about obstetrical and gynecological care in Ontario, with insensitivity, poor communication and lack of trauma awareness among the most common grievances.
Ontario's Patient Ombudsman Craig Thompson says his office received 168 complaints between April 2024 and March 2025, compared to 130 over the same period the previous year — a 29 per cent increase.
Complainants also detailed experiencing a lack of responsive care to factors such as history of sexual assault, pregnancy complications, miscarriages, and difficult births.
Many complaints were related to pregnancy, childbirth and postnatal care provided in hospitals, he said. There's also been an increase in complaints regarding services at community surgical and diagnostic centres that do ultrasounds, X-rays and surgical procedures.
Complaints are filed online, by email, fax or mail, and then reviewed by the ombudsman, who engages with both parties to reach a resolution.
National data from the Canadian Medical Protective Association suggests patient complaints across medical disciplines are on the rise, with more than 4,045 in 2020, up from 3,379 in 2016. They said many complaints showed communication was an underlying issue.
The Ontario ombudsman's data will be published later this year in an annual report on the overall number and themes of health-system complaints, but Thompson shared the OB/GYN numbers with The Canadian Press in the wake of an investigation published last week that included several patients alleging neglectful care going back almost a decade by the same Toronto doctor.
The patients described traumatic experiences while under the care of OB/GYN Dr. Esther Park, with some alleging they were not adequately informed about certain procedures performed at her clinic and the hospital she worked at for 25 years.
Dr. Park stopped practising medicine in April. Attempts to reach her for comment were unsuccessful.
In the ombudsman's last annual report released in March, the number of obstetrical and gynecological-related complaints in the province was described as an 'emerging concern' that Thompson said he would continue to monitor.
While Thompson said the way women's health is delivered in Ontario has been an issue for many years, he said what's new is the number of grievances about obstetrics and gynecology, and the nature of the complaints.
'We are in that role of a bit of the canary in the coal mine. We identify early signals of a problem,' he said, explaining that annual reports are shared with the province's ministries of health, long-term care, and relevant health agencies.
The patient ombudsman's role was created by the provincial government in 2016 to help resolve complaints and conduct investigations on issues of public interest.
Thompson calls his office the 'last resort' for patients who are not satisfied with a hospital's response to a complaint, and who need help reaching a resolution. But he also tries to pinpoint if a broader issue needs to be investigated and what can be done.
Thompson said he tries to determine: 'Where's the breakdown? Is this a breakdown in policy? Is this a breakdown in education or training of our team? Is this a breakdown in practice? Is the practice that we've adopted not meeting the mark?'
He would not disclose if he's conducting a broader investigation of obstetrical and gynecological care complaints. His last report included two pages on the practice, identifying 'broader organizational issues, including a lack of trauma-informed care approaches that, if addressed, could improve the experiences of patients and their families.'
Dr. Heather Millar, an obstetrician and gynecologist at Women's College Hospital and Mount Sinai Hospital in Toronto, says a trauma-informed approach begins with an awareness of how common painful childhood memories, sexual assaults and triggering medical encounters are. It also includes strategies to avoid traumatizing or retraumatizing a patient.
She said she first came across the method in 2015.
'I was working with a physician at the time who used trauma-informed care principles and I realized that this was something that we should all be doing and that really should be implemented across our specialty,' Millar said.
The premise is to treat each patient as though they have a trauma history, for instance asking permission before touching them and covering their bodies during an exam to facilitate an environment that feels safe.
Since then, Millar has been helping integrate the approach at hospitals, including within Mount Sinai's obstetric emergency training, and she teaches trauma-informed care to residents at the University of Toronto.
She's also working on national guidelines with the Society of Obstetricians and Gynaecologists of Canada (SOGC) to formally implement this approach as a standard of care.
'We're much more conscious now of how common trauma is in the general population … and also how the encounters and procedures in our specialty can be traumatic for people,' she said, referencing vaginal exams that can feel invasive, and emergencies during deliveries, which may trigger painful memories.
Dr. Glenn Posner, vice chair of education for the department of obstetrics and gynecology at the University of Ottawa, said when he was a resident more than 20 years ago, trauma-informed care was not talked about. But now, he sees residents bring this sensitive approach to their patients, for instance asking for permission multiple times before an exam, or showing them how a speculum feels on their leg before using it.
But the stressful demands of the job and sheer volume of patients can at times hinder sensitive communication, and can translate into body language that patients will pick up on, he said.
'Having a conversation with somebody with your hand on the door knob is perceived as you're rushing them. But you can spend the same amount of time or even less if you come in, pull up a chair, sit down.'
Similarly, Millar said there are small changes that can make patients feel more in control, such as raising the head of a hospital bed so that the physician can make eye-contact with them throughout an exam.
In response to an email from The Canadian Press containing the ombudsman's new data, the ministry of health said it expects every hospital and health-care partner to uphold the highest standard of patient care. They referenced existing patient safety legislation and regulation, but did not say what they would do about the increase in obstetrical and gynecological complaints.
'One complaint about the safety of care is too many,' a spokesperson for the ministry of health said in a statement.
The SOGC said it would not comment on the data since it has not seen the full report.
The head of an advocacy group that speaks out on behalf of patients says she's seen similar reports for years without any investment in changes.
'I am not surprised that there are more complaints that are coming in this particular area of practice,' said Kathleen Finlay, chief executive officer of the Center for Patient Protection.
Finlay, who has worked as a patient advocate for almost 20 years, said she often hears OB/GYN patients say, 'They didn't listen to me. I had a lot of concerns and I felt I was just being rushed through the process. My questions weren't being answered.'
She said not enough is being done at the regulatory level to make changes to improve patient experience.
'There are many issues that are, from a woman's perspective, very traumatic and so much of it is about not being treated with the respect that they deserve.'
This report by The Canadian Press was first published June 12, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Hannah Alberga, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
40 minutes ago
- CBC
Take tick precautions, but Lyme disease rates remain quite low on Prince Edward Island
More and more ticks have been catching a ride into the province of P.E.I. over the last few years. Ticks have been known to attach themselves to human skin, as well as hop onto furry pets, but medical experts say it's not causing a big jump in Lyme disease rates so far. CBC's Tony Davis reports.


CBC
40 minutes ago
- CBC
New patient targets for family doctors could hurt P.E.I.'s reputation, says national college
The College of Family Physicians of Canada is raising concerns over new targets for family doctors on P.E.I. and calling on all parties to work together to find a solution. "I'm feeling pretty sad. There seems to have been a significant breakdown in trust and in the relationship, and that's really hard, when people stop being able to trust one another," college president Dr. Carrie Bernard told CBC News: Compass host Louise Martin. Last week, the Medical Society of Prince Edward Island announced plans for legal action against Health P.E.I., citing what it says is a breach of its agreement with the province. The society said the new targets for how many patients each doctor needs to accept are not what it agreed to when it signed a new physician services agreement with the province last year. Bernard said that agreement, which made P.E.I. the first province to officially recognize family medicine as a specialty, a move that includes higher pay, was celebrated across the country. But she said the recent policy development undermines that progress and can make physicians feel not valued and respected by the system in which they play a foundational role. Health P.E.I.'s new operational guide includes key performance indicators, or KPIs, that include a requirement that each family doctor will see 24 patients a day, based on an average appointment being 15 minutes long. It also says each full-time family doctor should have a minimum of 1,600 patients on the books, or panel size, which Bernard calls an "arbitrary number." Penalties can be imposed if the minimum isn't met. Impact on recruitment and retention On Monday, P.E.I. Health Minister Mark McLane told CBC News that the targets are intended to help the government collect information and evaluate how the new physician services agreement is working. He also pointed out that Health P.E.I. was giving doctors and their association six weeks to provide feedback on the new guidelines, and said there will be no punitive measures during the first year of the agreement. P.E.I. health minister 'confident' province, family doctors can reach compromise on workload targets 4 days ago Duration 7:17 Health Minister Mark McLane responded for the first time to the legal battle brewing between the province's medical society and the P.E.I. government over new targets for how many patients family physicians see per day. McLane tells CBC News: Compass host Louise Martin that the guidelines are still in draft form, and says he wants to work with doctors to resolve their pending legal challenge. Bernard agreed that accountability matters. "I don't think any family physician thinks they should not be accountable. We expect the accountabilities, however, to be informed by the professionals who are actually providing the care," she said. The good news story 100 per cent was well shared across the country with great excitement, and right now there is a significant pause in that good news and a significant second look across the country about what's going to happen in P.E.I. — Dr. Carrie Bernard "This just sort of came out of nowhere, without consultation and discussion and collaboration and negotiation." She added that setting a blanket number for patient panels is too simplistic and doesn't reflect the reality of family practice. Bernard warned that just as the news of last year's agreement was celebrated across the country, this policy shift could have consequences on physician recruitment and retention. "Family doctors talk, and they talk to each other, not just to recruiters," she said. "So the good news story 100 per cent was well shared across the country with great excitement, and right now there is a significant pause in that good news and a significant second look across the country about what's going to happen in P.E.I." New target 'out of keeping' with national average Bernard said the 1,600 figure is "out of keeping" with the national average of about 1,200 patients per family physician. "The issue of numbers is that if a doctor has too many patients for the number of hours they have available to see their patients, you might have a family doctor in name, but you may not be able to actually see your family doctor," she said. She added that even the 1,200 average can vary greatly depending on the complexity of patients. Society representing P.E.I. doctors is suing Health P.E.I. over new targets for family physicians 7 days ago Duration 2:40 Health P.E.I. is planning to change how family physicians are expected to work in the province. The Medical Society of P.E.I. says that was not part of negotiations that led up to a new Physician Services Agreement, so it has initiated legal action, saying some doctors will leave the province over this. CBC's Stacey Janzer reports. For instance, doctors who serve many patients with chronic illnesses, as well as newcomers or refugee families who require translation, may need to spend more time per visit, which means they can handle fewer patients overall. The same is true for physicians with added responsibilities, such as teaching or taking on leadership roles in the community or hospital system, she said. "In smaller places like Prince Edward Island, where we're asking many family doctors to take on leadership roles — same thing," she said. "If you have to take on a leadership role, either in your family health team or at the hospital, that limits the number of patients you can see."


National Post
41 minutes ago
- National Post
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Article content Article content – Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ('MDD') with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) – Article content Article content – Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities – Article content – Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. Article content 'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.' Article content Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows: U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004. Article content Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Article content Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. Article content The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: Article content In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1 Article content Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2 Article content Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3 Article content President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4 Article content On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Article content Panel Title: Article content Date and Time: Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Sources Article content NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, (accessed June 9, 2025). Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, (accessed June 9 2025). The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, (accessed June 9 2025). The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, (accessed June 9 2025). Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content